Aurobindo Pharma | USFDA Approval– Aurobindo Pharma Limited has received final approval from the USFDA to manufacture and market their version of Mometasone Furoate Monohydrate Nasal Spray, which is equivalent to Nasonex Nasal Spray. – This new product will be launched in the first quarter of fiscal year 2025, potentially opening up new revenue streams for the company
Aurobindo Pharma | USFDA Approval
– Aurobindo Pharma Limited has received final approval from the USFDA to manufacture and market their version of Mometasone Furoate Monohydrate Nasal Spray, which is equivalent to Nasonex Nasal Spray.
– This new product will be launched in the first quarter of fiscal year 2025, potentially opening up new revenue streams for the company
Please follow and like us:
Comments are closed.